Your browser doesn't support javascript.
loading
Renal transplantation experience in a patient with factor V Leiden homozygous, MTHFR C677T heterozygous, and PAI heterozygous mutation.
Gülhan, Bora; Tavil, Betül; Gümrük, Fatma; Aki, Tuncay F; Topaloglu, Rezan.
Afiliação
  • Gülhan B; Department of Pediatric Nephrology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
  • Tavil B; Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
  • Gümrük F; Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
  • Aki TF; Department Urology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
  • Topaloglu R; Department of Pediatric Nephrology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey.
Pediatr Transplant ; 19(5): E126-9, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25996881
ABSTRACT
Vascular complications are important causes of allograft loss in renal transplantation. A two and a half-month-old boy was diagnosed with posterior urethral valve and progressed to end-stage renal disease at eight yr of age. During the HD period, a central venous catheter was replaced three times for repeated thrombosis. The boy was found to be homozygous for FVL and heterozygous for both MTHFR (C677T) and PAI. At the age of 12, renal transplantation was performed from a deceased donor. Postoperative anticoagulation therapy was initiated with continuous intravenous administration of heparin at the dose of 10 IU/kg/h. HD was performed for the first three days. By the fourth day of transplantation, his urine output had increased gradually. Heparin infusion was continued for 18 days during hospitalization at the same dosage. Thereafter, he was discharged with LMWH. On the third month after transplantation, his serum creatinine level was 1.1 mg/dL and eGFR was 75.7 mL/min/1.73 m(2). He has still been using LMWH, and his eGFR was 78.7 mL/min/1.73 m(2) eight months after transplantation. Postoperative low-dose heparin treatment is a safe strategy for managing a patient with multiple thrombotic risk factors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator V / Transplante de Rim / Inibidor 1 de Ativador de Plasminogênio / Metilenotetra-Hidrofolato Redutase (NADPH2) / Mutação Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Child / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator V / Transplante de Rim / Inibidor 1 de Ativador de Plasminogênio / Metilenotetra-Hidrofolato Redutase (NADPH2) / Mutação Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Child / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article